Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2022-03-09 Earnings Release
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 9, 2022, reporting the announcement of financial results for the year ended December 31, 2021. It includes a press release as Exhibit 99.1 but does not contain the full financial statements or detailed financial analysis itself. The text explicitly states that the press release is furnished and not filed, and the document is a current report rather than a full annual or quarterly report. The length is 3536 characters, which is relatively short and consistent with an earnings release announcement. Therefore, this document is best classified as an Earnings Release (ER) rather than a full Annual Report (10-K) or Interim Report (IR).
2022-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-08 English
FORM 3 SUBMISSION
Director's Dealing
2022-03-08 English
FORM 4 SUBMISSION
Director's Dealing
2022-02-18 English
FORM 4 SUBMISSION
Director's Dealing
2022-02-18 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the appointment of a new director and executive officer, details of employment agreements, stock option grants, and amendments to existing agreements. There is no financial statement or comprehensive financial data presented, nor is it an earnings release or annual/interim report. The primary subject is changes in the company's board and senior management, including compensatory arrangements. Therefore, the document fits the category of Board/Management Information (MANG). The document length and detail support a high confidence in this classification.
2022-02-18 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.